Apogee Therapeutics's gross profit for the
three
months ended in Mar. 2024 was $0.00 Mil. Apogee Therapeutics's gross profit for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00 Mil.
Apogee Therapeutics had a gross margin of N/A% for the quarter that ended in Mar. 2024 => No sustainable competitive advantage
Apogee Therapeutics Gross Profit Historical Data
The historical data trend for Apogee Therapeutics's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Apogee Therapeutics's Gross Profit
For the Biotechnology subindustry, Apogee Therapeutics's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Apogee Therapeutics's Gross Profit Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Apogee Therapeutics's Gross Profit distribution charts can be found below:
* The bar in red indicates where Apogee Therapeutics's Gross Profit falls into.
Apogee Therapeutics Gross Profit Calculation
Gross Profit is the different between the sale prices and the cost of buying or producing the goods.
Apogee Therapeutics's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as
Gross Profit for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
(Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Apogee Therapeutics had a gross margin of N/A% for the quarter that ended in Mar. 2024 => No sustainable competitive advantage
Apogee Therapeutics Gross Profit Related Terms
Thank you for viewing the detailed overview of Apogee Therapeutics's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.
Apogee Therapeutics (Apogee Therapeutics) Business Description
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. Its two most advanced programs are APG777 and APG808, which they initially develop for treating AD and COPD, respectively. With its broad pipeline and depth of expertise, the company believes it can deliver value and meaningful benefits to patients underserved by today's standard of care.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
APGE has been successfully added to your